WAVEMAN · COMPANY

BIIB · Biogen Inc.

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

BIIB

Name: BIOGEN INC. (BIIB) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

BIOGEN INC.

PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0000875045

CONGRESS · 2FORM 144 · 2☆ WATCH

INSIDER NET · 180D

-$239.7K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

555

13F, latest reported quarter

REVENUE GROWTH

+2.2%

XBRL, annual

NET MARGIN

13.1%

CONVERSIONS · 180D

codes C/M, not in net · $0 priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$239.7K over 180 days

-$239.7K over 90 days

more than 50% of Pharma & Biotech

CONGRESS

2 members bought in the last year

more than 65% of Pharma & Biotech

FUNDS

555 funds added or opened last quarter

more than 97% of Pharma & Biotech

REVENUE

+2.2% year over year

below 51% of Pharma & Biotech

MARGIN

13.1% net margin

more than 84% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

3.7% of shares outstanding short · 4.7 days to cover · settled 2026-07-31

below 54% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

555 funds added or opened positions in the latest 13F quarter, of 1,045 holders.

2 members of Congress reported buying it this year.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +58.2%

+58.2%12M

INSIDER BUYINSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows a net $239.7K sold by insiders over 180 days, 555 funds added last quarter, 2 Congress member(s) bought in 12 months, $239.7K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, BIOGEN INC. insiders sold a net $239.7K of stock across 26 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Minor Lloyd

Director

SELL

2026-08-04

593.0

$119.2K

Minor Lloyd

Director

SELL

2026-08-03

593.0

$120.6K

Murphy Nicole

Head of Pharm Ops and Tech

BUY

2026-02-12

3.0

$585

Singhal Priya

Head of Development

SELL

2026-02-09

2,660.0

$531.5K

Singhal Priya

Head of Development

SELL

2026-02-02

748.0

$134.1K

26 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 21 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

FMR LLC

18,217,239.0 sh

$3.9B

BlackRock, Inc.

15,985,736.0 sh

$3.5B

PRIMECAP MANAGEMENT CO/CA/

15,154,606.0 sh

$3.3B

VANGUARD CAPITAL MANAGEMENT LLC

9,651,117.0 sh

$2.1B

STATE STREET CORP

7,344,327.0 sh

$1.6B

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

Minor Lloyd

FILED 2026-08-04

$119.2K

Minor Lloyd

FILED 2026-08-03

$120.6K

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Invesco Biotechnology & Genome ETF

$12.5M POSITION · AS OF 2026-04-30

5.1%

VanEck Biotech ETF

$13.8M POSITION · AS OF 2026-03-31

3.7%

iShares Health Innovation Active ETF

$366.3K POSITION · AS OF 2026-04-30

3.6%

First Trust Nasdaq Pharmaceuticals ETF

$1.1M POSITION · AS OF 2026-03-31

3.6%

First Trust NYSE Arca Biotechnology Index Fund

$78.8M POSITION · AS OF 2026-03-31

3.5%

The Free Markets ETF

$604.0K POSITION · AS OF 2026-02-28

3.4%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 197 registered trials, 40 still enrolling or running — a status change here is dated weeks before the press release

Phase 1

6 ACTIVE

Phase 2

3 ACTIVE

Phase 3

16 ACTIVE

Phase 4

1 ACTIVE

Not applicable

13 ACTIVE

Multi-phase

1 ACTIVE

What changed recently

A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn Mo

2026-09-04 · Completion moved 2025-09-30 → 2030-06-04

Phase 1

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Corporate PAC

FEC · the company-connected political action committee's own receipts and spending — committee totals only, never individual donors

Biogen Inc. Political Action Committee A.K.A 'Biogen Pac'

CYCLE 2026 · $125K SPENT

$102.0K

FEDERAL ELECTION COMMISSION · MATCHED BY THE PAC'S CONNECTED ORGANISATION

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$9.9B	$9.7B	$9.8B	$10.2B
NET INCOME	$1.3B	$1.6B	$1.2B	$3.0B
EPS (DILUTED)	8.79	11.18	7.97	20.87
OPERATING CASH FLOW	$2.2B	$2.9B	$1.5B	$1.4B
LONG-TERM DEBT	$6.3B	$6.3B	$6.9B	$6.3B
BUYBACKS	—	$0	$0	$750.0M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE